Scrip
FDA grants label extension for Lilly's Forteo
24 July 2009
Katie McQue
Please Login to read the full article.
24 July 2009
Katie McQue
The US FDA has approved a label extension for Lilly's injectable parathyroid hormone agonist Forteo (teriparatide (rDNA origin) injection) to include the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women with a high risk of fracture.
"Patients...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA continues "safety review" of potential link between bisphosphonates and fractures
- NICE osteoporotic fracture guidance unchanged despite legal challenge
- US panel backs Amgen's denosumab for osteoporosis treatment but not prevention
- Canada approves once-monthly Actonel treatment
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
